Eledon Pharmaceuticals enters the final weeks of 2026 with a Phase 3 trial ready to open, a cleared IND in a second transplant type, and just enough cash to reach Q2 2027: $69.7 million on hand. The gap between that runway and what a 600-patient global trial demands is the number every reader should hold.
The LEGACY trial, designed to test tegoprubart against tacrolimus in kidney transplantation with a composite primary endpoint of biopsy-proven acute rejection, graft loss, and death at 52 weeks, is on track to enroll its first patients before year-end. The non-inferiority bar against tacrolimus is demanding: tacrolimus is today’s standard of care immunosuppression in kidney transplantation, and showing tegoprubart matches it on a hard composite while offering a cleaner tolerability profile is the trial’s entire commercial thesis. Supporting that thesis, long-term data from the Phase 2 BESTOW extension study showed tegoprubart-treated patients maintained roughly 13 mL/min/1.73m² higher kidney function than tacrolimus-treated patients at 24 months (71 vs. 58), with zero biopsy-proven acute rejection events beyond six months in the tegoprubart arm against seven in the tacrolimus arm. Those numbers will face harder scrutiny once LEGACY is powered to detect them at scale.
The islet cell transplantation program moved faster than the headline kidney story might suggest. The FDA cleared an IND for a company-sponsored registrational-path trial in type 1 diabetes patients receiving pancreatic islet cell transplants, and an investigator-initiated study at the University of Chicago Medicine Transplant Institute recently enrolled three additional subjects, building on previously reported results in 12 patients treated to date. All 12 patients treated to date achieved 100% insulin independence and demonstrated stable graft function through 22 months of follow-up, with no observed nephrotoxicity, hypertension, or neurotoxicity. Those are the side effects that calcineurin inhibitors like tacrolimus carry routinely, and their absence is tegoprubart’s core mechanistic argument: blocking the CD40/CD40L costimulatory pathway rather than broadly suppressing calcineurin leaves a narrower immunologic footprint.
FDA Fast Track designation, granted for kidney transplant rejection prevention, allows rolling review of completed data packages, which matters when a trial of this size will generate data in tranches over multiple years. The practical consequence: how far Eledon can extend its cash position past Q2 2027 before LEGACY produces an interim look determines whether the program stays in-house or becomes a licensing conversation.
Source link: https://www.sec.gov/Archives/edgar/data/1404281/000119312526458378/eldn-20261112.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
